glp-1 news today cardiovascular outcomes 2025 november In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with If you've had experience 5off Choose your Option:2-Month Supply

glp-1 news today cardiovascular outcomes 2025 november In the phase 3 ACHIEVE-1 trial, published in June 2025, the oral small-molecule receptor agonist orforglipron significantly reduced the glycated hemoglobin level over a period of 40 weeks in adults with If you've had experience 5off Choose your Option:2-Month Supply

If you've had experience with a GLP-1 (and are comfortable sharing), did you experience any effect towards the desire to drink? 🤔 💭 #weightlossdrugs #glp1 #alcoholcravings #drinkingless #gettingsober

[DOI] [PubMed] [Google Scholar] 72.Eng J, Kleinman WA, Singh L, Singh G, Raufman JP

5off

Choose your Option:2-Month Supply

Is that ruled out